MetaCap

RxSight Inc. (RXST)

NASDAQ: RXSTHealth CareOphthalmic GoodsUSD

4.47-0.14 (-3.04%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RXST stock chart

Technical analysis

Key statistics

All statistics
Market cap
$187.42M
EPS (TTM)
-$1.29
52-week range
4.11 – 13.22
Day range
4.45 – 4.75
Volume / Avg
539.31K / 826.96K
Beta
—

52-week range

$4.11$13.22

RXST stock today

RxSight (RXST) closed at $4.47 on Nov 20, down 3.04% (-$0.14), versus the S&P 500's 3.70% decline. Shares are 66.2% below their 52-week high of $13.22, set on Dec 11, 2025 and 8.8% above the 52-week low of $4.11, near the bottom of the past year's range. RXST is down 57.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 56.0%.

RxSight has posted a net loss over the last twelve months (EPS of -$1.29), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About RxSight

Company profile

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.

Industry
Ophthalmic Goods
CEO
Mr. Aziz Mottiwala M.B.A.
Headquarters
Aliso Viejo, CA
Employees
461
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, RxSight generated $134.5 million in revenue, down 3.9% from fiscal 2024, the first decline in the 6 years shown. RxSight reported a net loss of $38.9 million, compared with a loss of $27.5 million a year earlier. Gross margin was 76.6% (up from 70.7%) and operating margin -35.8%.

RxSight annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$134.48M$139.93M$89.08M$49.01M$22.59M
Growth-3.89%+57.09%+81.77%+116.90%+53.92%
Net income$-38.94M$-27.45M$-48.61M$-66.76M$-48.69M
EPS (diluted)$-0.95$-0.71$-1.41$-2.41$-3.57

Analyst forecast

Forecast

Consensus (10 analysts)

hold

Avg. price target

$6.10+36.47%

  • Strong buy 1
  • Buy 0
  • Hold 7
  • Sell 0
  • Strong sell 2

Target range

Low $5.00High $8.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.39 vs $-0.42
Surprise
+7.14%

RXST news

All RXST news

RxSight peers

Health Care sector
RXST peer companies
CompanyPrice% ChgMarket capCompare
LUCYInnovative Eyewear Inc.0.7025-0.07%$6.12Mvs RXST
STAASTAAR Surgical Company24.22-3.24%$1.22Bvs RXST
EYENational Vision Holdings Inc.16.72-1.70%$1.31Bvs RXST
WRBYWarby Parker Inc. Class A23.12-4.19%$2.87Bvs RXST
BLCOBausch + Lomb Corporation19.38-6.33%$6.93Bvs RXST
COOThe Cooper Companies Inc.58.88-2.40%$11.20Bvs RXST
ALCAlcon Inc.74.31-0.26%$35.70Bvs RXST

Indexes, lists and sector

RxSight stock FAQ

What is RxSight's stock price today?

RXST last traded at $4.47 as of Nov 20, 4:00 PM EST, down 3.04% on the day. Prices are delayed at least 15 minutes.

Who is RxSight's CEO?

Mr. Aziz Mottiwala M.B.A. is the chief executive officer of RxSight Inc., which has about 461 employees.

What is the RXST 52-week high?

The 52-week high for RXST is $13.22 and the 52-week low is $4.11. The stock is currently 66.2% below its high.

Compare RXST